Evenity Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to aging female population, high prevalence of postmenopausal osteoporosis, limitations of antiresorptive drugs, increased fracture related morbidity, early success of biologic bone therapies.

The growth in the forecast period can be attributed to growing awareness of bone health, increasing osteoporosis screening, expanding use of biologics, rising healthcare access for elderly populations, supportive reimbursement for fracture prevention. Major trends in the forecast period include rising use of anabolic osteoporosis therapies, growing focus on fracture risk reduction, preference for monthly injectable treatments, short duration high efficacy osteoporosis regimens, integration of biologic therapies in bone health.

The rising prevalence of osteoporosis is expected to drive the growth of the evenity market in the coming years. Osteoporosis is a condition characterized by reduced bone density and quality, leading to fragile bones that are more susceptible to fractures. The increase in osteoporosis cases is primarily due to an aging population with naturally declining bone density and sedentary lifestyles that weaken skeletal strength. Evenity is administered as a monthly injection for up to 12 months to treat osteoporosis by stimulating bone formation, reducing bone resorption, and strengthening bones to prevent fractures. For example, in February 2023, the Royal Osteoporosis Society, a UK-based charity, submitted written evidence estimating that fragility fractures cost the NHS $5.89 billion (£4.5 billion) annually, with hip fractures alone accounting for $2.62 billion (£2 billion) of that cost. Therefore, the increasing prevalence of osteoporosis is driving growth in the evenity market.

Rising healthcare expenditure is also expected to support the growth of the evenity market. Healthcare expenditure includes total spending on medical services, preventive care, medications, and health-related activities aimed at maintaining or improving population health. The increase in spending is driven by greater demand for medical care from an aging population and technological advancements that raise treatment costs. For Evenity, healthcare expenditure is allocated toward medication costs, strengthening healthcare infrastructure, and improving access to osteoporosis treatments, particularly for older populations. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Therefore, rising healthcare expenditure is fueling the growth of the evenity market.

The increasing number of drug approvals is also expected to propel the evenity market in the coming years. Drug approvals involve the formal evaluation and authorization of pharmaceutical drugs by regulatory authorities for public use. The rise in approvals is largely driven by advancements in biotechnology, which accelerate drug discovery, and supportive regulatory frameworks, such as accelerated approval programs, that streamline access to high-need medications. Drug approvals boost Evenity growth by expanding access to innovative treatment options, improving patient availability, and building confidence among healthcare providers. For instance, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, a 25% increase compared to the previous quarter. Therefore, the increasing number of drug approvals is driving the growth of the evenity market.

Major companies operating in the evenity market are Amgen Inc., UCB S.A.

North America was the largest region in the evenity market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the evenity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the evenity market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the evenity market by increasing costs related to biologic drug manufacturing inputs, cold chain logistics, and import of specialized injection devices. These impacts are more significant in regions dependent on biologic imports such as asia pacific and emerging markets. Higher costs may influence pricing and reimbursement decisions in hospital and retail pharmacy channels. At the same time, tariffs are encouraging regional biologics production and long term investments in localized pharmaceutical manufacturing capacity.

The evenity market research report is one of a series of new reports that provides evenity market statistics, including evenity industry global market size, regional shares, competitors with a evenity market share, detailed evenity market segments, market trends and opportunities, and any further data you may need to thrive in the evenity industry. This evenity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Evenity (romosozumab) is a biologic medication used to treat osteoporosis in postmenopausal women at high risk of fractures by inhibiting sclerostin, stimulating bone formation, and slowing bone loss. It is administered via monthly subcutaneous injections, typically for up to 12 months, after which alternative treatments may be recommended.

The main types of indications for evenity are postmenopausal osteoporosis and osteoporosis in men. Postmenopausal osteoporosis results from bone loss due to decreased estrogen after menopause and is treated with medications such as bisphosphonates and romosozumab. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving various end users, including hospitals and clinics, specialty centers, homecare settings, and research and academic institutions.

The evenity market consists of sales of products including evenity injection, evenity autoinjectors, and evenity pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.